Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients

Completed

• Conditions: Immune Deficiency; Thalassemia; Hemoglobinopathies; Fanconi Anemia; Sickle Cell Disease; Nonmalignant Diseases; Hematologic Malignancies; Genetic Inborn Errors of Metabolism
• Interventions: Drug: Thiotepa

• Registration Number: NCT03609840
• Lead Sponsor: University of California, San Francisco

Brief Summary

Thiotepa is a chemotherapy drug used extensively in bone marrow transplantation. Thiotepa is a prodrug that undergoes metabolic conversion in the liver by CYP2B6 and CYP3A4 to its primary active metabolite, triethylene phosphoramide (TEPA). The goal of this study is to determine what causes some children to have different drug concentrations of thiotepa and ...

Detailed Description

Thiotepa is an alkylating agent with potent antitumor and immunosuppressive properties used in conditioning regimens of pediatric hematopoietic cell transplantation (HCT) to promote stem cell engraftment. Thiotepa is a prodrug that undergoes metabolic conversion in the liver by CYP2B6 and CYP3A4 to its primary active metabolite, TEPA.
...

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2017-05-24
• Study First Submitted: 2018-01-05
• Study First Submitted QC: 2018-07-24
• Study First Posted: 2018-08-01
• Primary Completion: 2023-07-31
• Study Completion: 2023-07-31
• Status Verified: 2023-09
• Last Update Submitted: 2023-09-18
• Last Update Posted: 2023-09-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

1. be between 0 to 17 years of age;
2. meet protocol specific eligibility criteria for autologous or allogeneic HCT
3. will be receiving thiotepa as part of their conditioning regimen.

Read More

Exclusion Criteria

• Any child 7-17 years of age unwilling to provide assent
• Parent or guardian unwilling to provide written consent

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Pediatric Hematopoietic Stem Cell Transplant Recipients	Thiotepa	Children undergoing hematopoietic stem cell transplant (HCT) at University of California, San Francisco Benioff Children's Hospital

Primary Outcome Measures

Name	Time	Method
Analysis of the Area under the Plasma Concentration versus Time Curve (AUC) of thiotepa for HCT in pediatric patients.	24 hours post start of infusion	Area-under-the-curve (AUC) will be derived from the empirical Bayes estimates of individual clearance

Secondary Outcome Measures

Name	Time	Method
Event free survival according to the AUC of thiotepa	1 year post transplant	Death due to any cause within day 1 year post-transplant will be considered an event.

Trial Locations

Locations (1)

University of California, San Francisco; 🇺🇸 San Francisco, California, United States